Antibody-mediated rejection (AMR) is a recognized cause of allograft dysfunction in lung
transplant recipients. Unlike AMR in other solid-organ transplant recipients, there are no …

Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing
number of patients with cancer. Data suggest that up to 36% of cancer patients may be …

WITHDRAWN: Executive Summary - The International Society for Heart and Lung
Transplantation (ISHLT) guidelines for the care of heart transplant recipients - ScienceDirect Skip …

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide
interdisciplinary guidance on the management of immune-related adverse events (irAEs) …

Immune checkpoint inhibitors (ICIs) are approved for a wide range of malignancies. They
work by priming the immune system response to cancer and have changed the landscape of …

Background The introduction of solid-phase immunoassay (SPI) technology for the detection
and characterization of human leukocyte antigen (HLA) antibodies in transplantation while …

During the last 25 years, antibody-mediated rejection of the cardiac allograft has evolved
from a relatively obscure concept to a recognized clinical complication in the management of …

The Association for European Cardiovascular Pathology and the Society for Cardiovascular
Pathology have produced this position paper concerning the current role of endomyocardial …

The success of heart transplantation in the 1980s was enabled by the ability to diagnose
rejection by transjugular right ventricular endomyocardial biopsy, a technique developed by …

Heart transplantation (HTx) has become standard treatment for selected patients with end-
stage heart failure. Improvements in immunosuppressant, donor procurement, surgical …